CN101721680A - Application of variable lymphocyte receptor (VLR) of agnatha in pharmacy - Google Patents
Application of variable lymphocyte receptor (VLR) of agnatha in pharmacy Download PDFInfo
- Publication number
- CN101721680A CN101721680A CN200910219869A CN200910219869A CN101721680A CN 101721680 A CN101721680 A CN 101721680A CN 200910219869 A CN200910219869 A CN 200910219869A CN 200910219869 A CN200910219869 A CN 200910219869A CN 101721680 A CN101721680 A CN 101721680A
- Authority
- CN
- China
- Prior art keywords
- vlr
- application
- agnatha
- lymphocyte receptor
- pharmacy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention relates to the purpose of a substance, namely application of variable lymphocyte receptor (VLR) of agnatha in pharmacy, in particular to application of the VLR in preparing anti-pathogenic microorganisms, anti-tumor therapeutic drug and diagnosis. The VLR is a novel variable receptor discovered in agnatha and can identify different antigens specifically with affinity for the specific antigen, and the affinity is tens of times higher than that of the 1g G antibody. Due to the unique character of the VLR, the VLR is expected to be applied to antimicrobial injection, anti-tumor diagnosis and treatment like antibody drugs, even superior than antibody drugs. So far, the VLR is not available in application of the pharmaceutical field.
Description
Technical field
The present invention relates to a kind of purposes of material, i.e. the purposes of agnatha variable lymphocyte receptor body (VLR) in pharmacy, the especially purposes in making anti-invasive organism, antineoplaston medicine and diagnosis.
Background technology
Antimicrobial drug be use clinically at most, one of the widest medicine, in the control infectious disease, bringing into play important effect.But along with a large amount of abuses of antibacterials, invasive organism is spreading the drug resistance of antibacterials.Antibacterials have case the medication invalid condition to occur to the treatment of infected patient often.Can effectively address this problem, need go into overdrive to control the abuse of antibacterials on the one hand, be badly in need of new antibacterials on the other hand and replenish.
Generally the traditional antineoplastic thing is divided into plant bases, anti-metabolism, antibiotics, alkylating agent class, hormones, antibody class etc. clinically.At present, Chang Yong antitumor drug is above 80 kinds.In recent years, monoclonal antibody class and micromolecule tyrosine kinase inhibitor medicine have promoted the development of antitumor drug, and the speedup of newtype drug is far above conventional medicament.But at present on the China market newtype drug to account for the share of antitumor drug still lower, extensive use still is conventional medicament clinically.
The Cyclostomata animal claims agnatha again, mainly comprises Lampetra japonica (Martens). and hagfish 2 big classes.Variable lymphocyte receptor body (VLR) is a kind of new receptor of finding in agnatha.The gnathostomata vertebrates is by the specific immunity of antibody realization self, and agnatha is realized the specific immunity of self by variable lymphocyte receptor body (VLR).Variable lymphocyte receptor body (VLR) is meant by inserting at random in variable lymphocyte receptor body (VLR) gene and is rich in leucic repetitive and forms multifarious antigen recognition receptor, the antigen that specific recognition is different, the adaptive immunity of realization agnatha.Both can also there be secreting type VLR in variable lymphocyte receptor body (VLR) at agnatha quasi-lymphocyte surface expression, can be secreted in the serum.Secreting type VLR is the tetramer or the pentamer that is formed by connecting by disulfide bond by 4～5 dimers, and they have 8～10 antigen binding sites respectively.In morphology, there is high similarity in IgM with higher mammal.Variable lymphocyte receptor body (VLR) is higher tens times than IgG antibody-like to the affinity of specific antigen.Its exclusive characteristic is expected as the antibody class medicine even is better than the antibody class medicine to be applied in anti-microbial infection and antitumor diagnosis and treatment.Up to now, do not see that variable lymphocyte receptor body (VLR) uses in pharmaceutical field.
Summary of the invention
The present invention finds that the variable lymphocyte receptor body (VLR) of agnatha quasi-lymphocyte secretion generation has the using value of potential anti-invasive organism infection and aspects such as antineoplaston and diagnosis.With exogenous antigen (as invasive organism, tumor antigen etc.) immunostimulation agnatha, obtain to discern and in conjunction with high-affinity, the high specific variable lymphocyte receptor body (VLR) of specified microorganisms and tumor antigen by genetic engineering and protein engineering means.This kind receptor is higher tens times than the IgG antibody-like affinity that higher mammal produces.Therefore, variable lymphocyte receptor body (VLR) identification and in and specificity and the sensitivity stronger aspect the microorganism than antibody tool, to in invasive organism Infect And Diagnose and antimicrobial therapy, play a role, simultaneously, under the particular tumor antigens immunostimulation, this receptor makes it become the new type ideal instrument of targeting therapy for tumor and diagnosis to the superpower affinity that tumor antigen has.
The specific embodiment
With exogenous antigen (as invasive organism, tumor antigen etc.) immunostimulation agnatha, extract immunity back animal quasi-lymphocyte cDNA, clone's variable lymphocyte receptor body (VLR) gene from cDNA, can can discern and, utilize the DNA recombinant technique to realize the mass production of VLR and recombiant protein thereof by prokaryotic cell or eukaryotic cell protein expression system again by the screening of yeast cells or phage display technique in conjunction with high-affinity, the high specific VLR gene of specified microorganisms or tumor antigen.To satisfy the needs of industrialization pharmaceutical raw material.
Application in pharmacy mainly comprises following several respects about agnatha variable lymphocyte receptor body (VLR):
1, in conjunction with the biomarker technology, this kind VLR receptor can be used for assembling external diagnosis reagent case, be used for the invasive organism Infect And Diagnose and at tumor discovery, curative effect and the Prognosis of tumor markers, because of it is higher tens times than antibody class molecule to antigenic affinity, so it will have higher sensitivity and detection specificity based on the antibody class diagnostic kit than traditional.
2, VLR and recombiant protein thereof can combine with microorganism high specific, high-affinity, and microorganism is had neutralization, can prevent the microorganism invasion and promote its degraded and removing, thereby reach the effect of curing the disease.
3, VLR and recombiant protein thereof have the high special adhesion to tumor cell.VLR and medicine, enzyme or radiosiotope are combined together,, combine with the specific tumors cell or tissue in vivo, and produce therapeutical effect by its medicine that carries by VLR automatic guide effect.VLR has better affinity and specificity than monoclonal antibody, can take accurate aim and the acquisition target cell, reacts with target specifically, will play the effect of biological missile, performance other drug be beyond one's reach unique and remarkable usefulness.
Claims (3)
1. the application of agnatha variable lymphocyte receptor body (VLR) in pharmacy is characterized in that, comprises the application in pharmacy of VLR and recombiant protein thereof.
2. the application of variable lymphocyte receptor body according to claim 1 (VLR) in pharmacy is characterized in that, variable lymphocyte receptor body (VLR) is at the invasive organism Infect And Diagnose and make application in the anti-invasive organism medicine.
3. the application of variable lymphocyte receptor body according to claim 1 (VLR) in pharmacy is characterized in that, the application of variable lymphocyte receptor body (VLR) in tumor disease diagnosis and manufacturing antitumor drug.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910219869A CN101721680A (en) | 2009-11-13 | 2009-11-13 | Application of variable lymphocyte receptor (VLR) of agnatha in pharmacy |
| PCT/CN2010/075165 WO2011057504A1 (en) | 2009-11-13 | 2010-07-15 | Use of variable lymphocyte receptor (vlr) of agnatha in medicament preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910219869A CN101721680A (en) | 2009-11-13 | 2009-11-13 | Application of variable lymphocyte receptor (VLR) of agnatha in pharmacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101721680A true CN101721680A (en) | 2010-06-09 |
Family
ID=42443628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910219869A Pending CN101721680A (en) | 2009-11-13 | 2009-11-13 | Application of variable lymphocyte receptor (VLR) of agnatha in pharmacy |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101721680A (en) |
| WO (1) | WO2011057504A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011057504A1 (en) * | 2009-11-13 | 2011-05-19 | 辽宁师范大学 | Use of variable lymphocyte receptor (vlr) of agnatha in medicament preparation |
| CN103033617A (en) * | 2012-11-30 | 2013-04-10 | 辽宁师范大学 | Tumor marker detection kit based on variable lymphocyte receptors and method for preparing same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ550772A (en) * | 2004-05-21 | 2009-10-30 | Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
| CN101721680A (en) * | 2009-11-13 | 2010-06-09 | 辽宁师范大学 | Application of variable lymphocyte receptor (VLR) of agnatha in pharmacy |
-
2009
- 2009-11-13 CN CN200910219869A patent/CN101721680A/en active Pending
-
2010
- 2010-07-15 WO PCT/CN2010/075165 patent/WO2011057504A1/en active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011057504A1 (en) * | 2009-11-13 | 2011-05-19 | 辽宁师范大学 | Use of variable lymphocyte receptor (vlr) of agnatha in medicament preparation |
| CN103033617A (en) * | 2012-11-30 | 2013-04-10 | 辽宁师范大学 | Tumor marker detection kit based on variable lymphocyte receptors and method for preparing same |
| CN103033617B (en) * | 2012-11-30 | 2014-12-03 | 辽宁师范大学 | Tumor marker detection kit based on variable lymphocyte receptors and method for preparing same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011057504A1 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106103461B (en) | In conjunction with the carbohydrate ligand of the IgM antibody of anti-myelin associated glycoprotein | |
| CN106414477A (en) | Novel ultrashort hydrophobic peptides that self-assemble into nanofibrous hydrogels and their uses | |
| CN103342735A (en) | Tumor specific target polypeptide and application thereof | |
| JPH06500114A (en) | Bioactive EGF peptide for promoting tissue regeneration and treating cancer | |
| CN108368509A (en) | Improve the anti-IL-17 aptamers of blood retention | |
| CN101721680A (en) | Application of variable lymphocyte receptor (VLR) of agnatha in pharmacy | |
| CN104371009A (en) | GnRH polypeptide-methotrexate conjugate, and preparation method and application thereof | |
| WO2019154103A1 (en) | Novel polypeptide for tumor targeting and application thereof | |
| CN102060909B (en) | Tumor specific target polypeptide and application thereof | |
| CN104761629A (en) | A broadspectrum efficient antimicrobial peptide Pb-CATH-OH1, a gene thereof, a preparing method of the peptide and applications of the peptide | |
| CN101503473A (en) | Targeted polypeptide for diagnosing and treating lung cancer in vivo and in vitro and use thereof | |
| CN113845582B (en) | Application of endogenous polypeptide in preparation of targeted drug for preventing or treating endometrial cancer | |
| CN101143902A (en) | Anti-HER2 single-chain antibody-cefuroxime sodium enhanced fusion protein HER2(Fv-LDM) | |
| CN110672855B (en) | Use of actin-binding protein 2 in screening of medicaments for treating smooth muscle dysfunction diseases | |
| KR20150046006A (en) | System for Delivering Lectin-Based Active Ingredients | |
| US10100086B2 (en) | Peptide and uses thereof | |
| CN110225922A (en) | For promoting the agent and its method and purposes of angiogenesis | |
| CN105506170B (en) | Purposes of the SAV1 gene as fibroid diagnosis and treatment marker | |
| CN100371346C (en) | Artificial synthesized insulin-simulated peptide and its application | |
| CN109485712A (en) | Dimer Vc1.1-dimer, RgIA-dimer and PeIA-dimer | |
| Sweeney et al. | H. pylori’s BabA embraces change | |
| CN110551206B (en) | DNA aptamer for specifically recognizing MD-2 paclitaxel binding domain and application thereof | |
| US20240132621A1 (en) | Anti-chitinase-3-like protein-1 (ykl-40) neutralizing antibody and uses thereof | |
| CN1546522A (en) | Alkaline fibroblast growth factor antigen epitope peptide and its screening method | |
| Chaudhari et al. | Aptamer: A New Class of Oligonucleotide for Therapeutic and Diagnostic Use-Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100609 |